EIF2AK3 and ovarian carcinoma: Increased phosphorylation of JNK and PERK proteins by evodiamine was observed in ovarian cancer cells, and application of JNK inhibitors, including SP600125 (SP), jnk inhibitor (JNKI), and PERK inhibitor GSK260641, significantly inhibited evodiamine-induced apoptosis in human ovarian cancer cells, confirming the role of JNK, PERK, and caspase 3 in the cytotoxic activity of evodiamine.